Cresset Discovery Services Provides Computer-Aided Drug Design to Medicines for Malaria Venture
News Feb 13, 2016
Cresset Discovery Services, provider of contract research services for early phase discovery, and Medicines for Malaria Venture (MMV), have entered into a collaborative agreement to use computer-aided drug discovery to identify back-up compounds for a recently discovered molecule in MMV’s portfolio.
“Cresset Discovery Services offer expertise in computational chemistry,” says Dr James Duffy, Associate Director, Drug Discovery, MMV. “We look forward to working with them to identify a back-up compound for one of our promising projects.”
“Our experts in computational biology and computational chemistry are ideally placed to solve high impact problems in drug discovery such as the identification of back-up compounds,” says Dr David Bardsley, Commercial Director and Head of Cresset Discovery Services. “We’re delighted to be working in the fight against malaria.”
“The Cresset Discovery Services method is one of the most cost effective ways of providing a back-up series and represents an essential ‘insurance policy’ against late stage drug discovery failure,” explains Dr Martin Slater, Director of Cresset Discovery Services. “We will use the Forge molecular modeling software and the available SAR to deduce the most likely bioactive conformation of a recently discovered anti-malarial compound in MMV’s portfolio.
The most representative active conformer will be used in a Blaze virtual screen against a database of several million available compounds. From the output of the screen we will select the chemotypes that have the highest probability of showing a similar activity to the target. The results will be diverse chemotypes that are suitable candidates for back-up compounds.”
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE